{"id":"stavudine-extended-release-lamivudine-efavirenz","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication by blocking the HIV reverse transcriptase enzyme. Lamivudine is also an NRTI that targets the HIV reverse transcriptase enzyme. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to the HIV reverse transcriptase enzyme and blocks its activity, preventing viral replication.","oneSentence":"Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:30.494Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of HIV-1 infection in adults and children"}]},"trialDetails":[{"nctId":"NCT00005918","phase":"PHASE3","title":"Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00116116","phase":"PHASE4","title":"DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":"HIV Infections, AIDS","enrollment":70},{"nctId":"NCT00116298","phase":"PHASE3","title":"Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-01","conditions":"HIV Infections, AIDS","enrollment":900},{"nctId":"NCT00135369","phase":"PHASE3","title":"Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-09","conditions":"HIV Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"stavudine extended-release, lamivudine, efavirenz","genericName":"stavudine extended-release, lamivudine, efavirenz","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site. Used for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}